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Clinician investigators and biomedical scientists share a fundamental obligation to produce
new knowledge that can lead to better treatments or cures for human disease. Conflicts of
interest (COIs) occur when professional responsibilities and altruistic goals are influenced
by an outside interest that biases clinical judgement or interpretation of data. The public
exposure of a failure to disclose COIs in clinical or translational research can lead to a loss
of confidence in the medical profession and in scientific discovery, respectively. The
Sunshine Act was seen as mitigating the lack of transparency in COI reporting by requiring
the pharmaceutical and device industries to disclose all payments to physicians and
teaching hospitals through the Open Payment program, a public and searchable database
of industry payments. This database has certainly helped, but problems persist, as
illustrated by front-page articles in the New York Times describing how undeclared COIs
have roiled two major areas of medical research. The first New York Times reports detailed
the failure of a top cancer researcher and senior administrator at Memorial Sloan Kettering
Cancer Center to disclose over $3.0 million in compensation from industry (1). A follow-up
report noted that this high level of remuneration was not unusual for influential physicians
who serve on industry advisory boards (2). The second series of articles focused on a
former Harvard physician-scientist and […]
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Clinician investigators and biomedical 
scientists share a fundamental obligation 
to produce new knowledge that can lead 
to better treatments or cures for human 
disease. Conflicts of interest (COIs) occur 
when professional responsibilities and 
altruistic goals are influenced by an outside 
interest that biases clinical judgement or 
interpretation of data. The public exposure 
of a failure to disclose COIs in clinical or 
translational research can lead to a loss of 
confidence in the medical profession and in 
scientific discovery, respectively. The Sun-
shine Act was seen as mitigating the lack of 
transparency in COI reporting by requiring 
the pharmaceutical and device industries 
to disclose all payments to physicians and 
teaching hospitals through the Open Pay-
ment program, a public and searchable 
database of industry payments. This data-
base has certainly helped, but problems 
persist, as illustrated by front-page articles 
in the New York Times describing how 
undeclared COIs have roiled two major 
areas of medical research.
The first New York Times reports 
detailed the failure of a top cancer research-
er and senior administrator at Memorial 
Sloan Kettering Cancer Center  to disclose 
over $3.0 million in compensation from 
industry (1). A follow-up report noted that 
this high level of remuneration was not 
unusual for influential physicians who 
serve on industry advisory boards (2). The 
second series of articles focused on a for-
mer Harvard physician-scientist and stem 
cell biologist who had failed to disclose his 
association with a biotechnology company 
(3). After a five-year review, Harvard Medi-
cal School and Brigham and Women’s Hos-
pital (HMS-BWH) called for the retraction 
of 31 of his studies due, not to COIs, but to 
serious concerns regarding the integrity of 
data showing, in part, that c-kit+ stem cells 
could regenerate damaged heart (4). These 
two very different but equally high-profile 
events provide useful case studies of the 
adverse consequences that COIs can have 
on the integrity of research and can help 
guide development of improved reporting 
and oversight structures.
First, the Memorial Sloan Kettering 
case points out how academic institutions 
and professional associations often turn 
a blind eye to tracking and quantifying 
COIs, particularly when the conflict is held 
by a senior leader or a well-funded inves-
tigator. A failure to look for COIs and to 
appropriately regulate them is all too com-
mon across many professional societies. 
For example, the published policies of the 
National Comprehensive Cancer Network 
(NCCN) stipulate that authors of NCCN 
clinical guidelines may not have financial 
conflicts with the pharmaceutical industry 
that exceed a single payment of $20,000/
year or aggregate payments of greater than 
$50,000/year (5). A recent study found, 
however, that 86% of guideline authors 
had at least one conflict and that eight of 
125 authors had received payments over 
the benchmark levels (6). Societies have 
also failed to establish useful regulations 
for members of guideline committees. For 
example, the NCCN precludes members 
of guideline-writing committees from vot-
ing when they have a COI, but allows the 
conflicted members to stay in the room 
during those discussions at the discretion 
of the chair (5). In some cases, the con-
flicted panel members are even allowed to 
participate in the discussion. The NCCN 
guideline committees also need only have 
51% of its members to be free of conflicts, 
raising the concern that a panel in which 
nearly half its members are conflicted 
would be hard-pressed to avoid bias.
The Harvard/Brigham and Women’s 
Hospital case demonstrates a second lim-
itation of the Open Payment system — that 
it does not capture payments made to phy-
sician-scientists who do not maintain a 
medical license or to nonphysician inves-
tigators. Furthermore, companies that do 
not yet produce an FDA-approved product 
need not report payments to researchers. 
The Open Payment system also does not 
track the number of relevant patents that 
an investigator has filed with the US pat-
ent office, an important metric because 
it marks the intent of a faculty member 
to commercialize intellectual property at 
a later point in time. Thus, while current 
COI policies capture the “conflict” of a 
practitioner who attends a dinner spon-
sored by a pharmaceutical company, they 
fail to identify substantive conflicts among 
investigators who are leading clinical trials 
that might alter the care of patients.
A third flaw in COI policies at many 
academic institutions is a failure to prop-
erly oversee participation in clinical trials 
by investigators who have commercial-
ized their intellectual property and, as a 
result, have equity in the study sponsor. An 
absence of oversight often leads to investi-
gators participating in clinical studies that 
lack rigor in trial design, data collection, 
and/or are prone to overinterpretation of 
“encouraging” data buried in clinical end-
points that were not prespecified. In this 
regard, two recent reviews on the use of 
cardiac stem cells for regenerating heart 
muscle pointed out that recent stem cell tri-
als were rife with COIs (7, 8). For example, 
studies published in high-impact journals 
by investigators having an equity interest in 
the sponsoring entity or in a collaborating 
or contributing company reported salutary 
benefits of cell therapy in clinical trials that 
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and our failure to properly manage them 
threatens the integrity of the scientific pro-
cess insofar as it has the potential to bias 
scientific communications, which in turn 
will erode public trust in the scientific com-
munity. This statement notwithstanding, 
COI guidelines must not be so restrictive 
that they shackle academic freedom and 
stifle the entrepreneurial spirit of inves-
tigators. The scientific community must 
seek a transparent middle ground. The 
guidelines proposed herein may be viewed 
as too strident by some and too lenient by 
others, but they will hopefully serve as a 
starting point for national discussions with 
the goal of deriving new and innovative 
policies that are fair but also enforceable.
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How can academic institutions, pro-
fessional associations, and publishers 
redefine the ground rules for the disclosure 
and oversight of COIs in order to stem this 
growing problem? We propose that a few 
simple rules could go a long way toward 
increasing the public’s trust, as detailed in 
Recommendations for improving disclosure 
and oversight of conflicts.
The growing number of reported COIs 
enrolled fewer than 20 patients per treat-
ment group (9–11), lacked concordance in 
critical baseline demographic data (10), 
did not include a control group (9, 12), and/
or reported efficacy in the absence of a 
measured change in ventricular function 
(11). In fact, a randomized clinical trial that 
demonstrated a benefit of cardiac stem 
cells was subsequently retracted by the 
publisher because of questions regarding 
the validity of the data (13).
Finally, professional societies that sup-
port journals bear responsibility for mak-
ing sure that the editors and reviewers are 
made aware of all author COIs before pub-
lishing consensus documents. This is illus-
trated by a 2017 consensus statement on 
cardiomyocyte regeneration. The authors 
concluded that bone marrow–derived 
“c-kit+ cells or mesenchymal stem cells 
Recommendations for improving disclosure and oversight 
of conflicts
1. Published disclosures of COIs could be more meaningful if they divulged the amount of money 
received from relevant commercial entities. When possible, authors should reconcile these 
numbers with the Open Payment database.
2. Ownership in a private or public biotechnology company should be included in all disclosures 
as well as the value of the equity or the percentage of issued stock that is held.
3. Published patent applications filed with the US patent office should be included as 
potential COIs.
4. Guideline- and consensus-writing committees should exclude members with COIs or ask 
them to resolve their COIs before joining the committee. When that is not possible, those with 
COIs should be excused from the room during relevant discussions. The time-honored excuse 
that the best clinicians consult for every company because their opinions are so highly valued 
and that they therefore should not be excluded from writing committees is not a valid reason 
for ignoring the problems inherent with COIs.
5. A physician holding equity in a private or public biotechnology company or who serves as a 
director of a company should not participate as an investigator in any clinical trial sponsored 
by that company nor be a lead author on academic publications that report the study results. 
This is already a mandate at some, but far too few, academic centers in the US, and even when 
present it may be ignored.
6. Wherever possible, investigational new drug–enabling preclinical studies should be carried 
out by a clinical research organization and data analysis performed by an independent statisti-
cian, not by a trainee in the principal investigator’s laboratory.
7. Journal editors as well as guest editors must be free of all COIs, including equity and patents. 
Publication committees should raise questions when there is an imbalance in the types or out-
comes of studies published in their own journal as compared with those published by compet-
itors. Furthermore, lead editors should be judicious in submitting research articles to their own 
journal, limiting their submissions as far as possible to editorials and policy statements.
8. Academic institutions, publishers, and professional organizations must all share in the 
responsibility to ensure that COIs are appropriately reported, fairly adjudicated, and dealt with 
in a consistent manner.
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